Conclusions: To our knowledge, this study represents the first to describe CD10 expression in gliosarcomas. While negative in the glial components, CD10 always was positive in the sarcomatous components. Therefore, CD10 may be a useful marker for histologic delineation of sarcomatous elements of gliosarcomas. Whether or not CD10 plays a biologic role in gliosarcomas, akin to that in a number of other malignant neoplasms, remains to be elucidated.
Polyclonal
Clone K9 Clone DOG1. 
Conclusions:
ACCs, unlike salivary acinic cell carcinomas, do not express DOG1 to any significant extent. An earlier report of DOG1-positivity in SPNs likely represents non-specific staining. SMAs express DOG1, reflecting their ductal phenotype.
The Value of Arginase-1 Immunohistochemical Stain in Differentiating Hepatocellular Carcinoma and Metastatic Pancreas Acinar Cell Carcinoma as Compared To Glypican-3
Gokce Askan, Jinru Shia, Volkan Adsay, Carlie Sigel, David Klimstra, Ecmel IsikKaygusuz, Olca Basturk. Memorial Sloan Kettering Cancer Center, New York, NY; Emory University, Atlanta, GA; Zeynep Kamil Hospital, Istanbul, Turkey. Background: Glypican-3 and relatively newly identified arginase-1, effective immunohistochemical markers for identifying hepatocellular differentiation, have been widely used to diagnose hepatocellular carcinoma (HCC) and to distinguish it from metastatic carcinomas. However, glypican-3 has recently been reported to be also expressed by more than 50% of pancreatic acinar cell carcinomas (ACCs) (PMID: 23079207) . This creates a potential pitfall when evaluating tumors involving the liver as ACCs commonly metastasize to the liver. In this study, we explored the possibility of arginase-1 expression in ACCs. Design: A tissue microarray (TMA) of pancreatic ACC was created using 3 punches of 0.6 mm tumor for each case (n = 28). The TMA comprised 11 pure and 17 mixed ACCs [11 mixed acinar-neuroendocrine (MANEC), 4 mixed acinar-ductal (MADC), and 2 mixed acinar-neuroendocrine-ductal carcinoma (MANEDC)]. Acinar and neuroendocrine differentiations were previously confirmed by immunohistochemical labeling for trypsin and/or chymotrypsin and chromogranin and/or synaptophysin, respectively. Glypican-3 and arginase-1 immunohistochemical stains were performed on the TMA. If there was any positivity, the markers were repeated, along with HepPar-1, on a full-faced section of a representative tumor block. Strength and distribution of staining were evaluated. Results: None of the ACCs expressed arginase-1 but glypican-3 was positive (strong/ patchy to diffuse) in 7/28 (25%) of ACCs on both TMA and full-faced sections. One of the 7 glypican-3 positive MANECs was also labeled with HepPar-1 (strong/patchy) and another one revealed a few scattered HepPar-1 positive cells on full-faced sections. Conclusions: Although glypican-3 may be positive, arginase-1 appears to be uniformly negative in ACCs. Thus, its use may improve the accuracy in distinguishing hepatocellular carcinoma from metastatic acinar cell carcinoma.
Intraductal Oncocytic Papillary Neoplasm of the Pancreas Have Distinct Molecular Characteristics Than Intraductal Papillary Mucinous Neoplasm
Olca Basturk, Umesh Bhanot, Michael Berger, Peter Allen, Marcus Tan, Sasinya Scott, Ronak Shah, Volkan Adsay, Gokce Askan, David Klimstra. Memorial Sloan Kettering Cancer Center, New York, NY; University of South Alabama, Alabama, AL; Emory University, Atlanta, GA. Background: In 2010, the WHO reclassified the entity originally described as intraductal oncocytic papillary neoplasm as the "oncocytic-type" of intraductal papillary mucinous neoplasm (IPMN). Although several key molecular alterations of other IPMN types have been discovered, including common mutations in KRAS, GNAS, and RNF3, those of oncocytic-type have not been well characterized. Design: Eleven cases with features of oncocytic-type IPMN were identified. Of these, 9 revealed the entity-defining morphology of arborizing papillae lined by 2-5 layers of cuboidal cells with oncocytic cytoplasm and prominent, eccentric nucleoli as well as intraepithelial lumina. Of the other 2 cases, 1 had an unusual morphology characterized by a flat lining despite oncocytic cytology. The other was a predominantly pancreatobiliary-type IPMN with a distinct focus of oncocytic-type epithelium, and both components of this case were analyzed separately. For comparison, 2 biliary (intrahepatic bile duct) oncocytic papillary neoplasms were also analyzed. All specimens were microdissected, and deep coverage, targeted next-generation sequencing of 300 key cancer-associated genes was performed.
Results: Among pancreatic neoplasms, the number of mutations per case ranged from 1 to 10 (median=4). There were four repeatedly mutated genes, each in 2 of 9 typical oncocytic-type cases: ARHGAP26, ASXL1, EPHA8, and ERBB4. None of these 9 cases had KRAS or GNAS mutations and only one had RNF43 and PIK3R1 mutations. In the case with a flat lining, the only mutation was KRAS (the only KRAS-mutated case in the study). However, the one with both pancreatobiliary and oncocytic foci manifested TP53, GNAS and RNF43 mutations in both components and did not reveal any of the 4 mutations detected in the typical oncocytic-type cases. Thus, molecularly, it was similar to other IPMN subtypes. In the 2 biliary cases analyzed, the number of mutations per case was 8 and 4. The neoplasms did not have those 4 mutations, instead both revealed GNAS mutation, and one also had a PIK3CB mutation.
Conclusions: This small series suggests that when defined strictly, oncocytic-type IPMN has distinct molecular features compared to other types of IPMN and thus should be recognized separately. align with practical consequences, a two-tiered system (low vs high-grade) is proposed for all pancreatic precursor lesions, with the provision that the current PanIN-2 and intermediate-grade dysplasia are now categorized as low-grade. Thus, "high-grade dysplasia" (also designated "carcinoma in-situ" in some places) is to be reserved for only the uppermost end of the spectrum. 2)Intraductal lesions 0.5-1 cm can be either large PanINs or small (incipient) IPMNs. The term "incipient IPMN" should be reserved for lesions with long finger-like papillae, intestinal-type mucin or GNAS mutations. 3)Additional data are needed to determine if dysplasia at a margin in IPMNs lacking invasive carcinoma predict survival. Therefore, it is recommended to grade dysplasia at a margin even if PanIN cannot be distinguished from IPMN. 4)Conceptually, invasive carcinoma associated with an IPMN is genetically related to the IPMN; concomitant (independent) invasive carcinomas should be genetically distinct. Also, if sampling intervening tissue reveals continuity; invasive carcinoma associated with an IPMN is favored over concomitant. 5)Lesions resembling genetically engineered rodents' acinar-to-ductal metaplasia/atypical flat lesions exist in the human pancreas and may be an alternate pathway of cancer formation. However, their biological significance requires further study. Conclusions: These revised terminology and recommendations are expected to help improve practice in management of pancreatic precursor lesions, and our understanding of these processes.
Molecular Characteristics of the Pancreatic Intraductal Tubulopapillary Neoplasm
Umesh Bhanot, Olca Basturk, Michael Berger, Ronak Shah, Sasinya Scott, Volkan Adsay, Gokce Askan, Fatima Carneiro, David Klimstra. Memorial Sloan Kettering Cancer Center, New York, NY; Emory University, Atlanta, GA; IPATIMUP, Porto, Portugal. Background: Intraductal tubulopapillary neoplasm (ITPN)is a relatively recently described member of the pancreatic intraductal neoplasm family. By whole exome sequencing studies, the other member, intraductal papillary mucinous neoplasm (IPMN), was found to have several somatic mutations, often including KRAS, GNAS, and RNF3 genes, in the majority of cases. However, the molecular characteristics of ITPN have not been characterized. Design: Eleven ITPNs were identified in our institutions' surgical pathology files (10 with matched normal tissue). All neoplasms revealed the characteristic histomorphology -cellular intraductal nodules of back-to-back tubular glands lined by predominantly cuboidal cells with round to oval and atypical nuclei and no obvious intracellular mucin. All tested neoplasms immunolabeled with ductal differentiation markers (CK7, CK19, CA19-9, MUC1) but were negative for intestinal (CK20, CDX2, MUC2), acinar (trypsin, chymotrypsin) and neuroendocrine (chromogranin, synaptophysin) markers. The specimens were microdissected, and deep coverage, targeted next-generation sequencing was performed on a panel of 300 key cancer-associated genes. Results: The number of mutations per case ranged from 0 to 6 (median=2). None of the previously reported IPMN-related alterations were identified in these ITPNs. In fact, three cases (27%) did not reveal any mutations in the tested genes and only 2 specific genes were mutated in more than one case: MLL2 and MLL3, each identified in 2 cases. Six cases revealed amplification of MCL1. Conclusions: Intraductal tubulopapillary neoplasm is a distinct clinicopathologic entity in the pancreas. Although its intraductal nature and some clinicopathologic features resemble those of IPMN, our results suggest that it has distinguishing molecular characteristics. Further analysis of molecular alterations in this biologically distinct pathway including MLL2 and MLL3 (chromatin remodeling genes) will likely shed new light on the mechanisms of intraductal tumor formation in the pancreas and may uncover a new therapeutic target for patients whose tumors harbor these alterations.
Microscopic Invasion in Intraductal Papillary Mucinous Neoplasms of Pancreas
Deyali Chatterjee, Matthew Katz, Asif Rashid, Hua Wang, Gauri Varadhachary, Robert Wolff, Jeffrey Lee, Peter Pisters, Anirban Maitra, Jason Fleming, Huamin Wang. Baylor College of Medicine, Houston, TX; University of Texas MD Anderson Cancer Center, Houston, TX. Background: Intraductal papillary mucinous neoplasm (IPMN) is a grossly and radiologically distinct cystic neoplasm of the pancreas, 40-50% of which are associated with a component of invasive carcinoma. The prognosis is excellent for patients with non-invasive IPMN and poor for patients with IPMN with an invasive carcinoma. However the significance of microscopic invasion in IPMN is not clear. Design: All patients who were diagnosed with IPMN and underwent resection between January 1999 and December 2013 were included. All cases were reviewed for the degree of dysplasia, presence or absence of invasion, lymph node status, total sampling of the tumor, and pancreatic margin status. Microscopic invasion was defined as either unifocal or multifocal invasion of ≤5.0 mm with no grossly identified invasive component. Statistical analyses were performed using SPSS Statistics. Results: There were a total of 141 IPMN cases (54 females and 87 males) with median age of 67 years. IPMN with microinvasion was identified in 8 cases (5.7%). The clinical and follow up information was available in 117 patients (31 cases with low grade dysplasia, 29 with high grade dysplasia, 6 with microinvasion, 51 with invasive adenocarcinoma). Among 6 IPMN with microinvasion, 3 were located in the head, 2 in the body, 1 with diffuse involvement of entire pancreas and none had lymph node metastasis. Total sampling of the tumor was performed for 4 cases. During follow up two patients developed recurrence: one with local recurrence at 42 mo. who is alive with disease at the last followup, and one with metastasis to lung at 37 mo. who died of disease at 68 mo. For both cases, the tumors were not complete sampled. None of the 4 cases with complete sampling developed recurrence. Patients with IPMN and microinvasive carcinoma had similar survival to those with non-invasive IMPN and had better survival than those with an IPMN with invasive carcinoma. Conclusions: Our study showed that patients with IPMN and microinvasion had similar prognosis to those with non-invasive IPMN and had better survival than those with IPMN with invasive carcinoma. Our study highlights the importance of complete tumor sampling in IPMN without grossly identified invasive component. Jey-Hsin Chen, Howard Wu, Safi Shahda, Eunice Choi, Zijin Zhao, Jingmei Lin, Elena Chiorean. Swedish Medical Center, Seattle, WA; Indiana University, Indianapolis, IN; University of Washington, Seattle, WA. Background: Pancreatic ductal carcinoma is a highly malignant neoplasm with a propensity for aggressive locoregional invasion and metastatic spread. The pancreas is partially invested by the peritoneum, which when breached may increase the risk for intra-abdominal dissemination and recurrence. The histopathologic features of peritoneal invasion by pancreatic ductal carcinoma and their clinical significance have not been evaluated to date. Design: 83 surgical pathology cases (81 resections and 2 wedge biopsies) of pancreatic ductal carcinoma and variants involving the body and/or tail with extra-pancreatic extension were analyzed using routine and elastic stains and immunostains including pan-keratin and calretinin. The extent of tumor invasion of the peritoneum was divided into 3 groups: 1) no peritoneal involvement, 2) tumor invasion through the elastic lamina and into the submesothelial stromal tissue, and 3) tumor penetration of the peritoneal surface. The clinical history and data from institutional cancer registries were reviewed to determine the times and patterns of disease recurrence. Results: Tumor penetration of the peritoneum involves stepwise invasion of the elastic lamina, subserosa, and mesothelial-lined surface. Invasion of the subserosa is often associated with thinning, fragmentation, and retraction of the elastic lamina from the peritoneal surface and expansion of the submesothelial stroma. Of the 83 cases, 33 tumors did not involve the peritoneum, 20 invaded the elastic lamina and subserosa, and 30 perforated the peritoneal surface. Tumor invasion of the peritoneum (peritoneal surface and/or subserosa) was associated with an increased risk for recurrence (odds ratio 6.75, 95% CI=1.84 to 24.80), and all were associated with intra-abdominal recurrence and spread including malignant ascites. Conclusions: Invasion of the peritoneum is accompanied by architectural alteration that includes fragmentation and retraction of the elastic lamina and expansion of the submesothelial connective tissue. Localized peritoneal invasion by pancreatic carcinoma is associated with a significantly increased risk for tumor recurrence, particularly within the abdominal cavity, which may account for a mechanism for treatment failure in the surgical management of pancreatic carcinoma.
Histopathologic Features and Clinical Significance of Localized Peritoneal Invasion By Pancreatic Ductal Carcinoma
(LG) and 9 with high-grade dysplasia or invasive carcinoma (HG) from 22 patients. Both low and high grade components were evaluated separately in 2 patients. Exonic DNA of 300 cancer associated genes was sequenced, as well as 113 introns across 35 genes to detect rearrangement. Single nucleotide variants (SNVs) and indels were detected using MuTect and GATK. VisCapCancer was used to detect copy number variation. Results: KRAS mutations were most frequent, present in 9 (100%) HG and 3 (20%) LG tumors. HG lesions and a LG with concurrent HG showed missense mutations at Gly12 (9) and Gly13 (1), whereas variants in the 2 LG only cases consisted of a Gln61His mutation and an in frame deletion at Lys177. TP53 mutations were identified in 5 (56%) HG cases (3 nonsense, 1 frameshift, and 1 splice site mutation) but no LG cases. One SMAD4 mutation was identified in a HG case (11%). Additional genes with mutations in HG but not LG tumor included CTNNB1, PIK3CA, DNMT3A, ERCC4, MLL2, MSH2, STAG2 (in a TP53 mutant case), TCF7L2 (in a CTNNB1 mutant case), and U2AF1. Increased aneuploidy was observed in HG compared to LG cases, but FGFR3 loss was present in 27% LG cases vs. 11% of HG cases. CDKN2A loss was present in 5 (56%) HG tumors, 3 with codeletion of CDKN2B, but not in LG tumors. Low copy number gain of GATA6 was detected in 4 (44%) HG cases and 4 (27%) LG cases. Conclusions: Although KRAS mutations are not specific for HG neoplasia, different mutations are detected in those with only LG neoplasia. TP53 mutations and CDKN2A/B deletions are common in HG MCNs and are not seen in LG neoplasms suggesting that these mutations may be used as diagnostic markers preoperatively to identify lesions that warrant resection. Novel SNVs that occur at a lower rate demonstrate molecular heterogeneity in progression pathways and may provide a substrate for new diagnostic, prognostic and therapeutic targets. Todd DeJulio, Xiaoqi Lin, Haonan Li, Xiaoming You, Yihe Yang, Jie Liao, Nike Beaubier, Sambasiva Rao, Guang-Yu Yang. Northwestern University, Chicago, IL. Background: Pancreatic core needle biopsies are often difficult because of scant cellularity, a superficial biopsy or well-differentiated appearance. Many diagnostic features of ductal adenocarcinoma present on resections, such as perineural invasion, haphazard pattern, desmoplasia and anisonucleosis, are absent on core biopsies. Thus, identifying novel biomarkers for ductal adenocarcinoma would be a valuable tool in more accurately and definitively diagnosing these tumors. Multiple global gene expression modalities have shown overexpression of tissue transglutaminase II (TGM-2) in ductal adenocarcinoma, while TGM-2 is minimally expressed in nonneoplastic pancreatic ductal epithelium. In this study, TGM-2 expression is evaluated immunohistochemically on ductal adenocarcinoma and benign pancreatic core needle biopsies and on major resection specimens. Design: Twenty-five ductal adenocarcinoma and six benign pancreatic core biopsies and sixty nine resected pancreatic ductal adenocarcinomas were assessed. Paraffin sections were labeled with a rabbit monoclonal antibody to TGM-2 with appropriate positive and negative controls. Cases were scored as positive if dense cytoplasmic labeling was observed. Internal vascular endothelial cells served as a positive control. Results: More than 50% of the core biopsies were superficial in nature, consisting only of fragments of atypical epithelium without supporting stroma or acinar tissue. TGM-2 IHC showed that 80% (20/25) of pancreatic ductal carcinomas on core needle biopsy and 78% (54/69) on resected specimens showed diffuse and strong positive staining for TGM-2. All six of the benign pancreatic core needle biopsy cases and all adjacent normal pancreatic parenchyma in the resected specimens showed no positive staining for TGM-2. Capillary endothelial cells and desmoplastic stroma adjacent to invasive carcinoma in the resected specimens displayed intense TGM-2 staining.
Tissue Transglutaminase II Is a Novel Biomarker for Pancreatic Ductal Adenocarcinoma on Core Needle Biopsy and Resection Specimens

Conclusions:
Our results indicate that TGM-2 is a novel biomarker for pancreatic ductal adenocarcinoma that is sensitive and specific and is useful in supporting the diagnosis on core needle biopsies. Overexpression of TGM-2 in cancer-adjacent endothelial cells and desmoplastic stroma imply its role in tumor-stromal interaction and angiogenesis. A polyclonal antibody has been successfully generated from rabbits immunized with conjugated synthetic peptide. The current project is to study the expression pattern of TTMP in human pancreatic islets and pancreatic neuroendocrine tumors and to explore its role in regulating cell proliferation. Design: Immunostain for TTMP was performed on 19 well differentiated pancreatic neuroendocrine tumors with paired non-neoplastic pancreas. Based on intensity, the immunostain was graded as no staining (0), low intensity staining (+) or high intensity staining (++). To explore the functional effect of TTMP on cell proliferation, overexpression of TTMP was introduced by transfecting TTMP cDNA. Effect of TTMP on cell proliferation was evaluated by cell count in vitro. Statistical analysis was performed by using Fisher's exact test and student's t test. Results: Immunostains show a strong TTMP expression (2+) in normal pancreatic islet cells with an intracytoplasmic granular staining pattern. In contrast, there is a complete loss of TTMP expression in all of the well differentiated pancreatic neuroendocrine tumors tested (100%; 19/19). Pancreatic acinar and ductal cells are positive for TTMP but with only very weak cytoplasmic staining (0 to 1+). In vitro study shows TTMP overexpression significantly inhibits human cell proliferation (p<0.01). Conclusions: Expression of TTMP is completely lost in well differentiated pancreatic neuroendocrine tumors while TTMP overexpression blocks cell proliferation. Our results suggest that TTMP might be involved in pancreatic neuroendocrine tumorigenesis and progression. TTMP could be a useful marker in distinguishing pancreatic neuroendocrine tumor from normal pancreatic islets. Background: Bile duct brushing of pancreatic and biliary ducts is a specific but insensitive test for the assessment of malignancy. This study assesses the benefit of molecular testing with next-generation sequencing (NGS) relative to fluorescence in situ hybridization (FISH) in the accurate detection of malignancy. Design: Bile duct brushings collected from nineteen patients were subjected to cytological analysis, FISH using the UroVysion probe set, and targeted NGS using the SNaPshot assay. Specimens were placed into "negative"/"atypical" [true negative] or "suspicious"/"positive" [true positive] categories based on cytology and "negative" or "positive" categories based on FISH and NGS results. Performance characteristics for each diagnostic modality were calculated based on clinical follow-up or subsequent pathology indicating malignancy. Results: There were 10 malignant strictures (53 %) and 9 benign based on radiologic and/or follow-up pathological data. NGS revealed driver mutations in KRAS, p53, and/ or SMAD4 in 7/19 (37 %) cases, including 6 of 9 patients with malignancy (67 %). One KRAS mutant sample was benign on subsequent pathology (cholecystitis), possibly reflecting an unresected precursor lesion (e.g. biliary intraepithelial neoplasia). NGS for 2 patients failed. FISH results were positive in 7/19 (37 %) samples, including 6 of the 10 (60 %) patients with malignancy. Cytology was positive in 7 patients (37 %), suspicious in 2, atypical in 2, and negative in 8. Cytology was positive or suspicious in 9 of the 10 patients with malignancy. 0.5-5.9) . Pathology: Most (98%) were in the fundus; 4 were multifocal; 3 were diffuse ("adenomyomatosis"). AM presented as well-demarcated, nodular area of wall thickening, often forming a dimple in the overlying mucosa. Microscopically, a conglomeration of dilated glands (up to 14 mm), often radially converging to a point in the mucosa, but not individually opening to the surface (in contrast to RokitanskyAschoff sinuses) was noted. Variable amounts of muscle, often minimal around the deeper glands/cysts, were present. 9 (4%) revealed overt features of a duplication, by connecting to a well-defined lumen with circumferential muscle layer. Associations: Pyloric gland metaplasia was less common than controls (38% vs 52%); no other specific associations with stones, inflammation, cholesterolosis, intestinal metaplasia or thickening of the uninvolved GB wall (mean=3.6 mm vs 3.3 mm in control) were identified. Background: Lymph node metastasis is a significant prognostic factor in patients with pancreatic ductal adenocarcinoma (PDC). Although the number of positive lymph nodes is currently used to subclassify the pN stage in carcinomas of other organs, the prognostic significance of the number and ratio of positive lymph nodes in post-therapy pancreaticoduodenectomy (PD) is not clear.
Design:
The study population was comprised of 411 patients with PDC who completed neoadjuvant therapy and underwent PD at our institution between 1999 and 2012 (183 women and 228 men, with a median age of 64 years). All PD specimens were processed using a standardized pathologic evaluation system. The lymph node ratio (LNR) was calculated as a ratio of the number of positive lymph nodes to total number of lymph nodes dissected. The number of positive lymph nodes and LNR were correlated with clinicopathologic parameters and survival using SPSS statistics.
Results:
The total number of lymph nodes examined ranged from 5 to 68, with a median of 22. 189 (46%) of patients were node negative, while 222 (54%) of patients were node positive. Patients with node-negative disease had better disease-free survival (DFS) and overall survival (OS) than those with node positive disease (P<0.001 Conclusions: The number of positive lymph nodes and LNR are independent prognostic factors for survival in patients with PDC who completed neoadjuvant therapy and underwent PD. Subclassification of the N1 group to N1a (one positive lymph node) and N1b (>1 positive lymph node) is justified within this group of patients. Background: Pancreatic neuroendocrine neoplasms (PNNs) occur sporadically and in patients with multiple endocrine neoplasia type 1 (MEN1). In MEN1, multiple tumors have been shown to arise by independent clonal events. The purpose of the present study was to analyze clonality and microRNA (miRNA) profiling in neuroendocrine tumors from four MEN1 patients in whom the tumor was present in at least two separate sites, which included the pancreas, duodenum and the retroduodenal or peri-pancreatic lymph nodes. In one patient, there was tumor involvement in the right and left ovaries. Design: Clonality was assessed by MEN1 gene mutation and human androgen receptor analysis(HUMARA) assays. Normal and tumor DNA was purified from microdissected tissue by Qiagen DNA isolation kit. For the HUMARA assay, DNA was digested with HpaII or no enzyme; products were subjected to PCR with HUMARA primers and analyzed on the ABI 310 genetic analyzer. Total RNA was extracted using RecoverAll™ Total Nucleic Acid Isolation Kit (Ambion, Austin, TX, USA). MiRNAs expression was profiled using nCounter Human v2 miRNA Expression Assay (NanoString Technologies, Seattle, WA, USA) and raw data was analyzed using nSolver Analysis Software (V.1.1) and Excel. Background threshold was defined as the mean±1SD of negative controls. The expression difference was indicated as mean fold change.
Results: All the patients were positive for MEN1 gene mutation. HUMARA analysis in two of four patients revealed identical clonal patterns in the tumors from multiple sites in each patient. The clonal composition of the PNNs was not associated with a particular growth pattern, proliferation index or immunohistochemical expression pattern. Of the other two, one site was monoclonal which may represent an initial seeding event.
The profiling of 800 miRNAs showed differential miRNA expression between tumor tissues from different sites; 32 miRNAs showed increased expressions (miR-193b-3p, miR-215, miR-196b-5 notably) while 16 miRNAs were down-regulated (miR-148a-3p, miR-204-5p, miR-375). Interestingly, miR-210 was also upregulated in these samples, and this miRNA has been implicated in metastatic disease. Conclusions: These findings suggest that PNNs might initially represent poly/ oligoclonal neoplastic lesions which are eventually outgrown by a single, more aggressive cell clone with the potential for invasive growth and metastatic spread. The differentially expressed miRNAs may provide insights into the understanding of this cancer, and provide new tools for the development of new molecular targets. Conclusions: Differentially expressed miRNAs correlate with distinctive patient outcomes among PanNETs and may represent important surrogates of risk. Validation in a large, independent cohort of patients is needed to construct a miRNA signature predictive of outcome in these heterogeneous tumors. Background: Follicular pancreatitis is a recently described variant of chronic pancreatitis characterized by the formation of a discrete pancreatic mass and histologically by the presence of multiple reactive lymphoid follicles and the absence of histo-serologic features of autoimmune pancreatitis. This rare entity, recently reported from Asia in 2012, has not been reported in North America. Design: All pancreatic resections with a diagnosis of chronic pancreatitis were reevaluated. The histopathologic diagnosis of follicular pancreatitis was based on the presence of a prominent infiltrate of reactive germinal centers. Relevant clinical, radiologic and demographic data were collected. Immunohistochemistry for IgG4, Bcl2 and B-and T-cell markers were performed on the pancreatic tissue. Results: We identified 3 cases from our institutions which conformed to the histopathologic diagnosis of follicular pancreatitis. Two were pancreatectomy specimens and one was a core biopsy. The mean age of the patients was 57 years with a slight male predominance (M:F = 2:1). Pancreatic tumor was diagnosed incidentally in 2 cases while one patient presented with epigastric pain and fatigue. One case reported a history of ulcerative colitis. Radiologically, 2 patients showed a mass in the tail and body respectively while one (the symptomatic patient) showed only a diffuse dilatation of the pancreatic duct. Serum IgG4 was not elevated in two of the three cases examined. Histopathologic examination in all three cases showed numerous reactive germinal centers, located predominantly around pancreatic ducts. Storiform type fibrosis was not observed. A focus of obliterative phlebitis was seen in one case. Neutrophils were not present. The mean IgG4+ plasma cells was 10 per high power field and IgG4 to IgG ratio < 30%. The germinal centers were negative for Bcl2 and there was no evidence of a monoclonal B-cell proliferation.
Conclusions: Follicular pancreatitis is a distinct variant of chronic pancreatitis that clinically and radiologically may mimic a pancreatic neoplasm. Coexisting tumors were not uncommon(13%):NETs,7%, pancreatic/ampullary ca,2% and others,4%. FNA (was available in 4%) and was diagnostic in 1 case. Oligocystic SNs (OV), previously reported in major texts (WHO/AFIP) as accounting for 40% of SNs arising in the pancreatic head/neck of older men, constituted only 21% of our cases, was 1.7X more common in body/tail and affected younger females (F:M=4); 55% of OVs were multilocular, 45%, unilocular and they were often misread as mucinous cysts on imaging. Solid SN was least common (5 cases) and misread as NET on imaging. No SNs had malignant cytology or malignant behavior except for 1 previously reported consult case. 1 hepatic SN was VHL-associated, had classical SN morphology and was interpreted as an independent SN and not a metastasis. Six larger SNs (mean 113mm) showed adhesion to/direct penetration of adjacent tissues including LNs (n=4), stomach (n=1), spleen and colon (n=1). Background: Elucidation of the cancer-stroma interaction may hold the key for treating pancreatic ductal adenocarcinoma (PDA), one of the most rapidly lethal human cancers. Previous studies have demonstrated that the tumor microenvironment, composed of immune cells, myofibroblasts and extracellular matrix, plays a role in cancer development, progression and response to treatment. In addition, hypoxia, a defining feature of PDA, contributes to tumor progression. Successful multimodal neoadjuvant therapy have shown to alter the immunoregulatory balance of the tumor microenvironment. We aimed to determine the correlation between myofibroblast density, immune cell infiltrate and tumor-induced hypoxia in PDA following neoadjuvant therapy. Design: We performed immunohistochemistry (IHC) for smooth muscle actin (SMA) and hypoxia-inducible factor 1-alpha (HIF-1a) in a set of primary PDA upon which we have previously done an extensive characterization of their immune infiltrate. Samples included both, untreated (n=18) and neoadjuvant-treated cancers (n=20). Results were interpreted using a visual score and computer-assisted image analysis. Results: Stromal SMA expression in PDA was moderate (n=13) to high (n=14) in the majority of the 38 cases. Quantification of SMA expression using image capture and analysis software strongly correlated with visual SMA scoring (r=0.83, p<0.0001). A direct relationship between nuclear HIF-1 a expression by carcinoma cells and SMA expression by stromal myofibroblasts was noted. In addition, there was a tight correlation between SMA and CD3 (r=0.64, p=0.003), FOXP3+ regulatory T cells (r=0.62, p=0.004), and CD11b (r=0.55, p=0.01) in neoadjuvant treated tumors. Conclusions: Expression of SMA in stromal myofibroblasts of PDA following neoadjuvant therapy correlates with hypoxia and induction of a broad immune infiltrate including large numbers of potentially immunosuppressive FOXP3+ regulatory T cells and myeloid cells. Martin Jones, Zongli Zheng, Jessica Wang, Emily Albanese, Abdurrahman Kadayifci, Dora Dias-Santagata, Long Le, William Brugge, Carlos Fernandez-del Castillo, Mari Mino-Kenudson, A John Iafrate, Martha Pitman. Massachusetts General Hospital, Boston, MA. Background: The value of next-generation sequencing (NGS) of pancreatic cyst fluid (PCF) relative to the clinical impression and other pre-operative tests has not been well studied. Design: Ninety-two PCF specimens from 86 patients were analyzed by cytology, CEA and targeted NGS using the SNaPshot NGS assay. Cysts were classified by radiology and EUS reports (Clinical Impression pre-PCF Analysis) as non-neoplastic, serous cystadenoma (SCA), cystic neuroendocrine tumor (cNET), IPMN, MCN, malignant, or not-specified (NS). NGS results were compared to CEA (cut-off value of 192ng/ml) and to cytology with high-grade atypia (HGA) indicating a high-risk cyst. KRAS or GNAS mutations supported a mucinous cyst and GNAS mutation supported an IPMN. Results: Results are summarized in Figure 1 . NGS supported the clinical impression in 78% of cysts. For patients with a NS clinical impression, NGS supported a neoplasm in 29%. IPMN was confirmed by GNAS mutations in 22/92 (24%). A KRAS mutation reclassified as mucinous 19% of clinically non-neoplastic cysts with a nonmucinous CEA. One PCF with a clinical impression of cNET had cytology diagnostic of carcinoma. Seven (8%) PCF had either a TP53 mutation, or loss of CDKN2A or SMAD4. All 7 PCF also had either KRAS and/or GNAS mutations; 5/7 (71%) were clinically malignant and HGA was detected in 5/7 (71%). Overall, cysts nonmucinous by CEA were reclassified as mucinous in 45% of patients. All PCF with HGA on cytology (8/8) had mutations indicating a neoplasm, 6 malignant, 4 confirmed by unresectable imaging and 2 by histology. Histology in 13 patients (15%) showed 4 non-neoplastic (1 KRAS), 6 IPMN (all KRAS and 3 GNAS) and 3 malignant cysts (one KRAS, GNAS, TP53; 2 no mutations).
High Throughput Mutational Profiling of Biliary Neuroendocrine Carcinomas
Impact of Next-Generation Sequencing on the Clinical Impression of Pancreatic Cysts
Conclusions: NGS of PCF impacts patient management by defining or supporting a neoplastic process requiring follow-up or resection. In our series it was most valuable in identifying mucinous cysts with CEA < 192ng/ml. NGS may also offer prognostic information by identifying specific mutations, but this will require further investigation.
Somatostatin Receptor 2A and 5 Expression in Poorly Differentiated Neuroendocrine Neoplasms of Pancreatic and Extrapancreatic Origin
Bjorn Konukiewitz, Anna Melissa Schlitter, Abbas Agaimy, Irene Esposito, Gunter Kloppel. Technische Universität München, Munich, Germany; Universität Erlangen, Erlangen, Germany. Background: Most well differentiated neuroendocrine neoplasms (NENs) express somatostatin receptors (SSTR), especially SSTR2A and SSTR5. The expression of these SSTRs is of clinical importance for diagnosis, therapy and follow-up of well differentiated NENs. Little is known about the expression of SSTR2A and SSTR5 in poorly differentiated NENs (PDNENs). This study investigates the immunohistochemical SSTR2A and SSTR5 expression in PDNENs of different origin. Design: 29 PDNENs (all with a Ki67-index > 20%, including 10 from the pancreas/ ampulla, 7 from the colorectum, 5 from the bladder, 4 from the parotid gland, and 3 Merkel cell carcinomas of the skin) were analyzed by immunostaining for SSTR2A and SSTR5 (using a 3-tiered scoring system), synaptophysin, chromogranin A, CD56, p53, CK 20, and progesterone receptor (PR). Molecular analysis was performed for TP53 mutations. Pancreatic and colorectal PDNENs were compared with well differentiated NENs (WDNENs; with a Ki67-index > 20%) of pancreatic (n=4) and colorectal origin (n=2). Results: 4/29 PDNENs expressed SSTR2A (score 2 and 3) and 1/29 was SSTR5 positive. The SSTR2A-positive PDNENs resided in the pancreas (1/4), the colorectum (2/4) and the bladder (1/4). 17/25 (68%) SSTR2A-negative PDNENs showed nuclear p53 expression in more than 5% (range 7-95%) of tumor cells. 2/4 of the SSTR2A-positive PDNENs were also p53 positive. 5/6 WDNENs were negative for p53 and 4/6 of these tumors were positive for SSTR2A. All pancreatic and extrapancreatic PDNENs were negative for PR. CK20 was mostly detected in colorectal PDNENs and showed strong positivity in all PDNENs of the parotid gland. Conclusions: SSTR2A expression is not restricted to WDNENs but occurs also in single PDNENs. SSTR2A negativity in PDNENs correlates reciprocally with strong p53 expression. Pancreatic and colorectal WDNENs with a Ki67-index greater than 20% retain their SSTR2A expression. SSTR5 is only exceptionally expressed in PDNENs.
Comparison of Morphologic Subtypes of Intraductal Papillary Mucinous Neoplasm of the Pancreas With Their Mucin Immunoprofiles
Heewon Kwak, Xiuli Liu, Daniela Allende, Rish Pai, John Hart, Shu-Yuan Xiao. University of Chicago, Chicago, IL; Cleveland Clinic Foundation, Cleveland, OH. Background: Intraductal papillary mucinous neoplasm (IPMN) is divided into four histologic subtypes: gastric (G), intestinal (I), pancreatobiliary (PB), and oncocytic (O). The initial classification primarily used morphology without strict criteria for utilizing immunohistochemistry (IHC). In a concurrent study, we demonstrated moderate interobserver agreement among gastrotintestinal (GI) pathologists in classifying IPMN subtypes by morphology. This study compares IPMN subtypes diagnosed by morphology with their respective mucin (MUC) immunoprofiles. Design: Fifty IPMN cases were reviewed independently by 5 GI pathologists for IPMN subtyping by H&E morphology. A consensus diagnosis had at least 4 of 5 pathologists in agreement. IHC with MUC1, MUC2, MUC5AC, MUC6, and CDX2 was performed on 40 cases and quantitatively scored: 0 (no staining), 1 (<10% positivity of the lesional cells), 2 (10 to <50%), 3 (50 to <75%), or 4 (>75%). IHC results were grouped as negative (0-1) or positive (2-4). Results: IHC was performed on 29 IPMN cases (16 G-types, 8 I-types, 4 PB-types, 1 mixed type) with and 11 cases without a consensus diagnosis. Morphologic diagnosis was concordant with MUC1-, MUC2-, MUC5AC+, and CDX2-for 14/16 G-types and MUC1-, MUC2+, MUC6-, and CDX2+ for 7/8 I-types. MUC6 positivity was seen in 10/16 G-types. PB-types had variable immunoreactivity with all markers except MUC2, which was negative in all cases. Background: Pancreatic ductal adenocarcinoma (PDAC) remains a very aggressive disease with few promising treatment options. WGS provides a powerful platform for deep insight into disease-related and therapy-relevant genomic alterations. Due to often extremely low tumor cellularity, heterogeneity, and desmoplasia, WGS of primary PDAC is a formidable challenge. We illustrate an integrated enrichment workflow that provides very high-quality WGS data from primary PDAC. Design: LCM was performed on frozen tumor samples (typically 200,000 tumor cells per NGS library), while FS was used with fresh tissue (EpCAM positive selection). Sequencing was performed on HiSeq2000/2500 instruments at 50× (tumor) and 35× (germline) depth. Results: Whole genome sequencing of 102 fully tumor-cell enriched PDACs has been completed. In the LCM-enriched cohort, the per patient median number of observed whole genome SNV was 5278, the median number of non-synonymous exonic mutations was 38, and the median number of indels was 456. In the flow-enriched cohort, the median per patient observed whole genome SNV was 5866, the median number of non-synonymous exonic mutations was 41, and the median number of indels was 537. The most commonly mutated genes were KRAS (90%), TP53 (55%), SMAD4 (10%). Importantly, however, there was a long tail of mutated genes (∼50), each of which is mutated in 5-8% of patients (e.g., MUC16, ARID1A, CDKN2A), highlighting the degree of genomic heterogeneity within PDAC. A small subset (n=5) of PDACs in our cohort show a "hypermutated" phenotype (>300 non-silent exonic mutations or >20,000 mutations in the genome). Chromotryptic (large-scale genome rearrangement) events also appear commonly (50-60% of cases) and may be associated with p53 status. A mutational signature analysis tentatively identified at least 4 distinct genomic PDAC subtypes. Conclusions: Systematic use of LCM and FS prior to WGS has significantly improved the ability to call somatic mutations, and perform copy number and structural analyses. PDAC is a genomically heterogeneous disease. Pathway mapping of the alterations is under way. LCM and FS coupled with WGS is a powerful combination that would also be applicable to other cancers that are characterized by high intrinsic heterogeneity and/or low cancer cell content but also to the study of cancer-associated non-neoplastic compartments (such as tumor stroma). [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] were identified from our institutional database (n=383). All cases were categorized into benign, reactive change, adenoma, adenocarcinoma or other based on morphology alone. Immunohistochemistry (IHC) for p53, Ki-67 and HMGA2 were performed on randomly selected slides from each category with appropriate controls. Epithelial cell nuclear positivity from 5 high power fields was determined for each biomarker and cases with more than 5% positive epithelial cells were considered positive results. Results: Normal ampullary mucosa was seen in 24% of cases (n=91) while 45% had reactive epithelial change (n=171), 20% were adenomas (n=77), 10% were adenocarcinomas (n=40) and 1% were other (n=4). Cases with reactive epithelial change demonstrated inflammation and/or fibrosis (n=136), pseudostratefication and hyperchromasia similar to adenomas (n=41), or cytological atypia suspicious for adenocarcinoma (n=19). p53 was positive in 75% of adenocarcinoma cases, but negative in cases with adenoma or reactive epithelial change. Ki-67 was diffusely positive in the proliferative zone with extension to the luminal surface in all adenoma cases (topdown growth pattern), but was limited to the epithelial proliferative zone in all cases of reactive epithelial change. HMGA2 was positive in 80% of adenocarcinomas, 8% of cases with reactive epithelial change and none of the adenomas.
IHC of IPMN Subtypes with a Consensus Diagnosis
Ampullary Biopsy Morphology Combined With a Three Biomarker Panel Is a Unique Approach To Distinguish Adenomas and Adenocarcinomas From Reactive Epithelial Change: A Large Cohort Study
Conclusions:
We demonstrate that morphology together with a three biomarker panel is a unique approach to differentiate reactive epithelial change from adenoma and adenocarcinoma in limited ampullary biopsy material. Malignant biomarkers p53 and HMGA2 are useful and sensitive in diagnosis of ampullary adenocarcinoma while Ki-67 highlights a top-down growth pattern in adenomas to distinguish them from reactive epithelial change. (Fig. A) . 2) Round nuclei (in 15): basal/suprabasal, large, round, uniform cuboidal nuclei with prominent nucleoli; moderate cytoplasm, some clear, some acidophilic (Fig. B) . 3) Tall columnar (in 8): gastric/endocervical-like; nuclei compressed at the periphery (Fig. C) . 4) Grooved-nuclei (in 6): minimal/moderate cytoplasm; visible nuclei with uniform chromatin but subtle grooves (Fig. D) . 5) PTC-like crowded nuclei (in 3): overlapping, elongated, hypo-chromatic nuclei with high N/C. Differential Diagnosis: 1) AschoffRokitansky sinuses, which, unlike EWDs, formed compressed units perpendicular (and often connecting) to the surface, undulating contours, columnar cells with acidophilic cytoplasm and basal/suprabasal usually elongated nuclei with dense, homogenous chromatin, without nucleoli. 2) Proliferative metaplastic glands. Small, round, clustered (not dispersed), relatively uniform glands with small lumina; some with pyloric mucin; uniform nuclei; fine chromatin. F/U: Median surv. was 26 mos. 11 (55%) rapidly died of disease (at a median of 6 mos). Of the 9 (45%) that were alive, 5 lived >10 yrs, 3 of whom had very limited T2 ca.
Clinicopathologic Analysis of 21 Deceptively Benign-Appearing Adenocarcinomas ("Adenoma Malignum") of the Gallbladder and Their Differential Diagnosis From Pseudoinfiltrative Processes
Conclusions:
Recognition of the patterns elucidated in this study can be crucial in the challenging differential diagnosis of extremely well differentiated GBC from their benign mimics. Although low grade, these are still aggressive with a median survival of ~2 years. However, patients with low stage may experience long-term survival. (89) 51 (89) 55 (91) 57 (96) 56 (98) 0 0 Conclusions: This study is the first to comprehensively examine claudin expression in pancreatic WDNETs. Pancreatic WDNETs lack strong claudin 4 expression in contrast to rectal WDNETs. Islet 1 and PAX8 are frequently expressed in rectal carcinoids, limiting their specificity for pancreatic WDNETs. However, the Islet 1+/PAX8+/claudin 4-immunophenotype appears to be specific for pancreatic WDNETs. Background: Because of a lack of unique clinical features, a histological examination is essential for diagnosing type 2 autoimmune pancreatitis (AIP).The diagnostic hallmark of type 2 AIP is neutrophilic infiltration in the duct epithelium and/or lumens (granulocytic epithelial lesion; GEL). However, this finding is only rarely obtained in biopsy tissues, and thus biopsy diagnosis of type 2 AIP depends partly on lobular inflammatory changes of the pancreas, which have not been discussed in detail to date.
Claudin Expression in Well Differentiated
We compared the histological features of resected type 2 AIP and pancreatic ductal adenocarcinoma (PDA) in order to clarify histological characteristics and the specificity of lobular inflammation in type 2 AIP. Design: Resected specimens of type 2 AIP (15 cases) and PDA (47 cases) were selected for the study. The histological patterns in type 2 AIP were classified based on types of the predominant epithelial changes [A: remaining of acinar cells, B: acinar-ductal metaplasia (ADM), C: loss of the majority of the epithelium] and types of stroma and inflammatory infiltration (0: edema without inflammatory cells, 1: edema with inflammatory cells, 2: fibrosis). For each case, the first and second most prominent patterns were recorded. Types of inflammatory cells and GEL in the intralobular ducts were also observed. Cases with PDA were then examined to find similar histological features. Results: Among the histological patterns, the B-1 pattern was the most significant (seen in 13 cases), and was usually associated with the C-1 pattern. Neutrophilic infiltration was observed in all cases, notably in the areas with ADM, but the degree of the intensity was varied. There was one case of the C-2 and C-1, and C-1 and A-0 patterns, respectively. GEL in the intralobular ducts was observed as prominent in 3 cases, and mild in 9. In the former cases, the duct epithelium was so severely disrupted that the recognition of GEL was often difficult. The B-1 pattern was also common in PDA cases, being identified in 27 (57%) out of 47 cases. This finding was most often seen at the infiltrative margin of PDA. Conclusions: ADM with neutrophilic infiltration was the predominant pattern seen in the lobules of type 2 AIP. Although this finding resembles GEL, ductal metaplasia is a pathological structure, and thus distinct from GEL, which affects pre-existing ducts. ADM with neutrophilic infiltration is not specific, and is commonly seen even in cases of PDA. As a result 33/91 cases (36%) were placed in a different grade based on whether Ki(h) or Ki(r) was used for grading (p<0.001). The agreement between KI(h) and mitotic index was also weak (K, 0.126). Most importantly KI(h) was more predictive of metastasis (p=0.015) and tumor size (p=0.0006) than KI(r) (p=0.0712 and p=0.07 respectively). For tumors >5cm KI(h) trended toward predicting perineural invasion (PNI) (p=0.055) but KI(r) did not (p=0.089).
Conclusions:
There is significant intratumoral heterogeneity in Ki67 distribution in primary pancreatic NETs, which, depending on sampling and area counted may lead to underestimation of grade in 36% of cases. This study supports the current approach of using hot spots as the grade parameter, by illustrating a stronger association of hot spot count with signs of aggressiveness such as metastatic risk, tumor size and PNI, than random. This has significant implications for KI calculation in biopsies and cytology samples. 1998 -2014) , was stained for four MMR enzymes (MLH1, MSH2, MSH6 and PMS2). MMR-deficiency (MMR-d) was defined as an absence of nuclear staining in tumor cells for any of the MMR enzymes, while presence of nuclear staining was interpreted as a MMR-proficient (MMR-p) profile. Univariable disease-specific survival (DSS) was assessed using the Kaplan-Meier method, while Cox-Proportional Hazards Model was performed to calculate multivariable DSS. Results: Of the 236 patients, 77 (33%) were treated with an adjuvant pyrimidine analog and 58 (25%) showed a MMR-d immunoprofile, while 178 (75%) were MMR-p. In the MMR-p cohort, adjuvant chemotherapy, pathological stage, perineural invasion and the presence of tumor budding were significant prognostic variables of DSS; however, no difference existed amongst the two cohorts with regard to these variables. The distribution of MMR profiles in relation to adjuvant chemotherapy and median DSS are shown in Figure 1 .
Mismatch Repair Status as a Predictive Marker in Pancreatic Ductal
Conclusions:
In our cohort, adjuvant chemotherapy with a pyrimidine analog conferred no advantage to MMR-d PDAC patients. MMR immunoprofiling appears to lend itself as a feasible step to guide therapy in PDAC and prospective evaluation of this finding is warranted. Background: Overexpression of ELAFIN (serine protease inhibitor of elastases and neutrophil proteinase 3) in a variety of malignancies including carcinomas and glioblastoma has been reported. Proposed mechanisms that induce ELAFIN overexpression include hypoxia and its location on a commonly occurring amplicon (20q12-13.1). Published reports suggest that elafin expression impacts outcome in a tumor specific manner, i.e. correlation with good prognosis in breast carcinoma vs poor prognosis in glioblastoma and decreased sensitivity to genotoxic agents in high-grade serous ovarian carcinomas. We report ELAFIN expression across a broad spectrum of carcinomas and identify malignancies with previously unreported expression. Design: ELAFIN expression by immunohistochemistry was scored in 1,302 tumors (26-147 tissues/tumor subtype). All tissues were collected under IRB approved protocols and anonymized. Results: We observe strong positivity for ELAFIN in a subpopulation of carcinomas of the bladder (18%), breast (5%), cholangiocarcinoma (32%), colorectal (54%), endometrial (37%), gastric (35%), hepatocellular (2.6%), lung adenocarcinoma (7.5%), mesothelioma (3%), ovarian (20.7%), pancreatic (56%) and renal cell (2%) as well as the expected positivity in various squamous cell carcinomas (41-76%). No melanomas, basal cell carcinomas or papillary thyroid carcinomas with strong expression were identified. A significant correlation of elafin mRNA levels and sensitivity to the PI3K/mTOR inhibitor NVP-BEZ235 in a large panel of pancreatic cancer cell lines was observed (Fisher's exact test, p=0.0161). Pathway analysis of genes overexpressed in elafin-high cells suggests active roles of PTGS2 (COX-2), NFkB-complex and PI3K signaling. Conclusions: Aberrant ELAFIN expression is observed in a previously unreported spectrum of adenocarcinomas, including a subset of gastrointestinal adenocarcinomas. elafin's genomic location is within an amplicon that contains numerous oncogenes associated with the progression of colorectal adenomas to adenocarcinomas and metastatic potential and is frequently observed in intrahepatic cholangiocarcinomas (67%), colorectal carcinomas (>70% in HNPCC), gastric carcinomas (up to 77.8%), pancreatic (up to 100% in some subtypes). Preliminary data in pancreatic cancer cells support a possible role for elafin expression as indicator for a response to targeted therapies. Further studies are necessary to corroborate and elucidate whether this correlates with progression and is informative in predicting response to genotoxic agents in the other malignancies. status was tested by quantitative peptide nucleic acid (PNA) clamp PCR in 207 and 54 cases respectively. Mutations were confi rmed by Sanger sequencing. A subset of 20 cyst fl uids were analyzed by ion torrent sequencing for KRAS, GNAS, BRAF, PIK3CA, VHL, CTNNB1, TP53 and SMAD4 mutations. Both methods can detect a 1% mutation frequency. DNA quality/quantity was evaluated using multiple methods. Cyst fl uid CEA and amylase levels were also measured. Clinical follow-up data was obtained.
Elafin Expression in Gastrointestinal Neoplasia and Correlation
NGS Sequencing Augments Cytologic Evaluation of Pancreatic Cyst Fluids
Results: Cytology diagnoses were classifi ed into four groups: non-diagnostic (ND, group 1, 24%), negative (NEG group 2, 56%), atypical/suspicious (group 3, 17%), and positive for malignancy (group 4, 4%). Three samples (1.4%) failed mutation analysis. Mutation frequency was as follows: KRAS (38%, 81/211), BRAF V600E (0.5%, 1/211), GNAS (20%, 11/54), VHL (10%, 2/20). In cases with GNAS activating mutation, 73% (8/11) were also KRAS mutated. Mutational analysis of cytology groups showed the following. Group1: KRAS (40%, 20/50), BRAF (0%, 0/45), GNAS (38%, 3/8), VHL (33%, 2/6). Group2: KRAS (20%, 23/116), BRAF (1%, 1/111), GNAS (12%, 4/33), VHL (0%, 0/11). Group3: KRAS (85%, 29/34), BRAF (0%, 0/29), GNAS (50%, 4/8), VHL (0%, 0/3). Group4: KRAS (83%, 5/6), BRAF (0%, 0/6), GNAS (0%, 0/3), VHL (0%, 0/0). Surgical resection was performed in 27 patients. Among 18 KRAS mutated cases, there were 8 intraductal papillary mucinous neoplasm (IPMN), 6 mucinous cystic neoplasm (MCN), 1 PaNIN-3, 2 adenocarcinoma and 1 chronic pancreatitis (CP). Among 9 cases with wild-type KRAS, there were 2 IPMN, 4 MCN, 1 SCA, and 2 CP. Of 6 surgicals with prior GNAS analysis, 3 were KRAS/GNAS positive (IPMN) and 3 were KRAS/GNAS negative (MCN, SCA, Pseudocyst). Conclusions: Mutation analysis is a good adjunct to cytological evaluation of pancreatic cyst fl uid, especially for ND/NEG specimens. In our study, KRAS was positive in 50% of 14 MCN/IPMN cases with a ND/NEG diagnosis.
Stromal Palladin Expression Is an Independent Prognostic Factor of Pancreatic Ductal Adenocarcinoma (PDAC)
Daisuke Sato, Tomoko Mitsuhashi, Takahiro Tsuchikawa, Yutaka Hatanaka, Toru Nakamura, Satoshi Hirano, Yoshihiro Matsuno. Hokkaido University Hospital, Sapporo, Japan; Hokkaido University Graduate School of Medicine, Sapporo, Japan. Background: Recently, it has been clear that tumor microenvironments including cancer associated fi broblasts (CAFs) in the stroma play an important role in PDAC progression. Although remarkable progress in chemoradiotherapy (CRT) for PDAC has been noted, how CAFs relate to the patients' prognosis and the effect of CRT on CAFs have not been fully investigated. The aim of this study was to evaluate the prognostic implication of palladin, one of the actin-associated proteins reported to be a specifi c marker of CAFs in PDAC, and also to investigate the changes of its expression in PDAC after CRT. Design: Firstly, to investigate CAFs' prognostic implications, tissue micro arrays (TMA) representing 167 resected PDACs without preoperative treatment were used for immunohistochemical studies (IHC) of palladin, α-smooth muscle actin (SMA), and podoplanin. Correlations between the expression levels of these markers and clinicopathological fi ndings were statistically analyzed. Secondly, to investigate changes in CAFs after CRT, surgically resected specimens of PDACs with (CF, n=19) and without (SF, n=21) preoperative CRT were studied by IHC and analyzed in the same way. Results: In TMAs, disease specifi c survival rate (DSS) at 5 years of all 167 cases was 23%. Seventy-one cases (42%) were positive for palladin and had signifi cant lower DSS (p=0.043, Fig. 1 ). α-SMA and podoplanin were positive in 167 cases (100%) and in 133 cases (80%), respectively (not related with DSS). On multivariate analysis, palladin expression was an independent prognostic factor (p=0.019, risk ratio 1.65). CF group had signifi cant higher DSS than SF group (p=0.036). Regarding CRT effects in CF, 4 cases corresponded to Evans' grade I, 8 to IIa, 4 to IIb, 0 to III and 3 to IV. Five of 19 in CF and 16 of 21 in SF were palladin positive. Palladin expression was signifi cantly lower in CF (p=0.0037), and much lower around degenerated tumor cells (p=0.017). DSS was signifi cantly lower in palladin positive cases in CF subgroup analysis (p=0.014, Fig. 2) . Conclusions: Stromal palladin expression is an independent prognostic factor of PDAC. It might also be a prognostic biomarker after CRT in PDAC. Results: General characteristics: 70% were intrahepatic, and 30% extrahepatic. Mean tumor size was 6.9 cm. All neoplasms had the defi ning histomorphologic characteristics -they were composed almost exclusively of non-mucinous tubular units with/without sheet-like growth, with no or minimal abortive papilla formation, in addition to comedocarcinoma-like pattern (35%), clear cell areas (15%), oncocytoid cytology (15%), calcifi cations/psammomas (15%), colloid-like secretions (10%), and "mallory-like" hyaline globules (5%). Invasion was seen in 80%, mostly in the form of tubular adenocarcinoma. With a median follow up of 44 months, 5-year survival was predicted as 90%. Mucin expression: By defi nition, none of the neoplasms expressed MUC5AC. MUC1 labeling was seen in 80% and MUC6 in 30%, while MUC2 was absent. Immunohistochemical and molecular analysis of common oncogenic pathways: TP53 alterations were rare, detected in 17% of intraductal components (vs 9% of invasive). Mutated KRAS as well as mutated PIK3CA were identifi ed only in 6% of intraductal components (vs 0% of invasive). Similarly, SMAD4/DPC4 inactivation was identifi ed in 7% of intraductal components (vs 0% of invasive (n) LGD (96) IGD (25) HGD (2) INV ( While multiple prognostic classification systems exist, they do not consider the underlying biology of these tumors. Whole exome studies have identified recurrent mutations in the α-thalassemia/mental retardation syndrome X-linked (ATRX) gene, which results in loss of ATRX protein expression, within a subset of PanNETs. ATRX loss was initially reported to be associated with a favorable prognosis; however, more recent studies suggest the opposite. In order to assess the prognostic significance of ATRX loss, immunolabeling for ATRX was performed on a large cohort of PanNETs and correlated with various clinicopathologic factors. Design: 110 surgically resected PanNETs were immunolabeled for ATRX. Cases were scored as ATRX-negative in the absence of nuclear staining within neoplastic cells, while retained within surrounding non-neoplastic pancreatic parenchyma. Immunostaining results were correlated with patient demographics, pathologic features, disease-free survival (DFS) and disease-specific survival (DSS). The follow-up period ranged from 1.6 to 18.8 yrs. Conclusions: Loss of ATRX protein expression is a poor prognostic factor and associated with disease recurrence and decreased survival in patients with PanNETs after resection. Considering the presence of intratumoral heterogeneity, ATRX loss may be late event within the pathogenesis of PanNETs. Aatur Singhi, Randall Brand, Asif Khalid, Jennifer Chennat, Kenneth Fasanella, Kevin McGrath, Georgios Papachristou, Adam Slivka, N Paul Ohori, Liron Pantanowitz, Herbert Zeh, Amer Zureikat, Melissa Hogg, Kenneth LGD, 2 serous cystadenomas (SCA), 2 cystic pancreatic neuroendocrine tumors, 2 lymphoepithelial cysts, 1 acinar cell cystadenoma, 5 pseudocysts, and 1 retention cyst. All IPMNs harbored a KRAS and/or GNAS mutation, while TP53 (n = 4) and PIK3CA (n = 1) mutations were only identified in IPMNs with adenocarcinoma. A homozygous rather than a heterozygous mutation in GNAS was seen in the IPMN with HGD. A deletion in PTEN was found in the MCN, and both SCAs had VHL mutations. No mutations were identified in the remaining cysts. Among IPMNs with adenocarcinoma, preoperative cytopathology was suspicious for adenocarcinoma (n = 2), atypical (n = 2) or negative (n = 1). The only adenocarcinoma diagnosed by cytopathology was a retention cyst on resection, which lacked mutations. Conclusions: Mutational analysis of EUS-FNA obtained pancreatic cyst fluid for KRAS and GNAS, and VHL were highly specific and sensitive for IPMNs and SCAs, respectively. In addition, TP53 and PIK3CA analysis provides a useful adjunct in screening for adenocarcinoma arising in an IPMN. While further studies are required, the 6-gene panel described herein may serve as an important diagnostic and prognostic tool in the assessment of pancreatic cysts. Design: HSP90 expression was assessed in 6 GBC cell lines and 209 tumors from archival tissue samples by Western Blot and immunohistochemical methods, respectively. The in vitro effects of GA and 17-AAG on cellular viability and migration were evaluated by MTS and Transwell migration assays. The potential therapeutic effect of 17-AAG was evaluated by a subcutaneous tumor model in immunosuppressed NOD/ SCID mouse. When the tumor in the xenotransplant reached 100 mm 3, the animals were treated with 25 mg/kg of the inhibitor or it vehicle (DMSO) during 5 days for a period of 4 weeks. The animals were then sacrificed and tumor volume and weight were evaluated. Results: HSP90 was positive in 182 tissue samples (33% intense, 28% moderate, and 26% weak) and negative in 27 cases (13%). HSP90 inhibition in vitro with GA and 17-AAG on cell lines induced cytotoxicity and significantly reduced the cellular migration and the expression of client oncoproteins of HSP90. Treatment with 17-AAG in the subcutaneous tumor significantly reduce the weight and tumoral volume when compared with the control group. Conclusions: Our results suggest the HSP90 is highly expressed in primary tumors and GBC cell lines. This is the first report of using HSP90 inhibitors as a potential therapeutic alternative in GBC treatment. (Fondecyt 1130204, FONDAP ACCDiS). Conclusions: Even with available diagnostic modalities, PD procedures performed for presumed tumor resection yielded the postoperative histopathologic diagnosis of "chronic pancreatitis" in a significant number of cases (13. 4%). In 13 cases with radiologic diagnosis of mass lesion or cystic lesion, no neoplasm was identified in the PD specimen. Distal periductal fibrosis and proximal duct dilatation as well as enlarged pancreas with or without calcifications (14 cases) yielded the diagnosis of chronic pancreatitis as expected. This study gives us a perspective of unneccesay PD with resultant morbidity and mortality, which may be avoidable. Furthur correlated studies are needed to eliminate the 13.4% PDs without pancreatic adenocarcinoma. Design: Orthotopic pancreatic tumors were induced in 20 SCID mice using a novel technique. Low dose electrocoagulation of pancreas under laparoscopic guidance (using Coloview-mouse colonoscope) with thin electrode, followed by injection of 0.1 cc BxPC3 pancreatic cancer cells was done (n=12, study group). Control mice underwent electrocoagulation alone (n=4, group 1) and tumor cell injection alone (n=4, group 2). Mice were evaluated for tumor growth and metastasis by necropsy (4 and 8 weeks for experimental group; 8 weeks for control group).
Targeted Six-Gene Panel in the Preoperative Diagnosis and Prognostication of Pancreatic Cysts
HSP90 Expression and Antitumoral Activity of Geldanamicin and Its Analog in Gallbladder Carcinoma
Pa n c r e a t i c o d u o d e n e c t o my ( P D ) W i t h o u t Pa n c r e a t i c
Results: Tumors were detected in 11/12 mice in experimental group, 1/4 in control group 2, and none in control group 1. The histopathological features in these murine models were found to be similar to that of human. Over time an increase in tumor growth, tumor volume, lymphovascular invasion of pancreas, with metastasis to lymph nodes and surrounding organs were noted. Background: Pancreatic adenosquamous carcinoma is an uncommon and aggressive pancreatic malignancy that has yet to be fully characterized. C-MYC is a transcription factor that functions in cell growth, differentiation and apoptosis, and is amplified in numerous lymphoid as well as gastrointestinal malignancies but is poorly characterized in pancreatic ductal adenocarcinoma (PDA). Here we evaluated the presence of C-MYC amplifications in PDA using whole exome sequencing (WES) and Fluorescence in situ hybridization (FISH). Design: Whole exome sequencing was performed on 109 PDA case. TruSeq Exome Enrichment (FC-121-1048) was used to build libraries that were subjected to pairedend whole exome sequencing using Illumina HiSeq2500 platform. Data processing and analysis were performed using Broad Institute Firehose pipeline. To obtain copy number alterations GISTIC 2.0 module version 6.2 with join segment size = 4 and confidence level = 0.95 was used. Fluorescence in situ hybridization (FISH) was preformed on selected cases subjected to WES and additional 15 cases of ASC using Vysis LSI MYC dual color "break-apart" rearrangement probe. Increased copy number was defined as 4-5 C-MYC signals per call and amplifications as >6 signals per cell. Kaplan-Meier plots were used to evaluate association with survival. Results: Interrogation of amplified and deleted regions for association with survival revealed that the amplification of the 8q24 region, harboring the MYC oncogene, was associated with poor outcome (p=0.0013). The amplification of C-MYC was confirmed by FISH. C-MYC amplified cases were overrepresented in the adenosquamous subtype of PDA. Analysis of additional 15 cases of adenosquamous carcinoma by FISH revealed, 4 cases with increased C-MYC copy number and 5 cases with amplification. Combined analysis of WES and FISH revealed amplifications in 11 of 27 pancreatic adenosquamous carcinoma cases (41%).
Conclusions: These data demonstrate that C-MYC amplifications are common in this particularly aggressive pancreatic cancer subtype and provide a potential therapeutic target in a disease with an otherwise dismal prognosis. Background: Despite extensive efforts, the overall survival for pancreatic ductal adenocarcinoma (PDA) is unchanged. The host immune response, characterized by immune cell infiltrate and their products, is the primary barrier to tumor development and a potential therapeutic target. We investigated the lymphocyte, neutrophil and plasma cell infiltrate in PDA epithelium and stroma. Additionally, we evaluated the immunohistochemical expression of programmed death-ligand 1 (PD-L1), forkhead box P3 (FOXp3) and CD163 and their relationship to clinicopathologic parameters. PD-L1 expression (on tumor epithelial and immune cells) as well as infiltration of FOXP3 expressing T regulatory cells and CD163 positive M2 macrophages contributes to immune anergy however detailed analysis of these makers has not been simultaneously performed in a large cohort of PDA patients. Design: Tumor tissue-microarrays with 203 PDA cases annotated with clinicopathologic data were stained for PDL-1, FOXp3 and CD163. Peri-tumoral and intra-tumoral neutrophils, lymphocytes and plasma cells were assessed using whole tissue sections corresponding to TMA cases and scored as absent, mild to moderate or strong based on number of cells. IHC markers were stratified into low and high expression groups based on published criteria. Survival curves were plotted based on individual and combinatorial biomarker status and correlations were determined. Unsupervised, random forest clustering was then performed to determine specific PDA phenotypes and their relationship to prognosis. Results: PDL1 correlated with a higher tumor grade (p=2.37x10 -4 ) however there was no relation of expression to overall survival. Presence of FOXP3 expressing T regulatory cells did not portend worse survival, while infiltrate of CD163 positive M2 macrophages correlated with shorter overall survival (HR 2.438, p = 0.002). High peri-tumoral neutrophilic infiltrate was noted in PDAs with particularly poor prognosis (p = 0.0455), and plasma cell infiltrate trended toward worse survival (p=0.069). No correlation with survival was noted regarding lymphocytic infiltrate. Random forest clustering yielded 3 immune infiltrate defined subtypes. The worse prognosis cluster was characterized by low expression of PDL1, high positivity for CD163 and FOXp3 and had a mean survival of 20 months. In contrast, low expression of PDL1, CD163 and FOXP3 was associated with mean survival 26 months, though these differences did not achieve statistical significance (p = 0.553). Conclusions: Our findings provide characterization of immune cell infiltrate in PDA and may help in immune based therapies.
that microRNA-145 (miR-145) expression decreases with the progression of PACa, allowing aberrant expression of MUC13. Restitution of lost levels of miR-145 may prevent PACa progression by down-regulating MUC13 expression. Design: A pilot study using six-week-old athymic Nu/nu mice was carried out to investigate the effect of miR-145 restitution. Mice were divided into three treatment groups,control (six mice), non-targeting control mimics (NC, six mice) and miR-145 (six mice). Tumors in mice were implanted by injecting PACa HPAF-II cells, having high MUC13 expression, into the right flank subcutaneously. After the tumors developed, (avg. volume 80 mm 3 ) miR-145 mice group was injected intratumorally with miR145 mimics 9 times. Tumor growth was followed for 21 days until the tumors reach 700 mm 3 . The mice were then euthanized followed by the analysis of tumor growth, volume and metastasis. Tumor volumes were examined as a function of time (discreet), group (control, NC, and interaction between them. Results: We demonstrate thatthe tumor growth and volume regressed drastically with miR-145 replenishment in mice compared to control and NC treated mice. On investigation of mice tumors, we found that the tumors from miR-145 treated mice had drastic reduction in the expression of MUC13 and its target HER2 using in-situ hybridization and immunohistochemistry techniques. This suggested an important role of miR-145 in the inhibition of pancreatic tumor growth by directly targeting MUC13.
Conclusions:
The current study provides important insights into the tumor suppressor role of miR-145 in a well-known tumor-promoting network that includes MUC13. The study delineates the association of alterations in miR-145 levels with MUC13 expression that may have a potential role in initiation and progression of pancreatic ductal carcinoma. miR-145 induced down-regulation of MUC13 is associated with tumor growth reduction in pancreatic xenograft mice model, highlighting miR-145 as an attractive modulator of MUC-13 in stemming the initiation and growth of PACa.
Morphology and Molecular Evidences of Malignant Potential of Entrapped Ducts in Pancreatic Neuronendocrine Tumors
Wendi Zhou, Jayalakshmi Panicker Balakrishna, Wei Zhang, Abdelsalam Sharabi, Violette Ghali. Mount Sinai St. Luke's -Roosevelt Hospital and Beth Israel Medical Center, New York, NY. Background: Pancreatic endocrine tumors are well documented for containing entrapped small, cytologically bland ductules. However, pre-neoplastic changes of those entrapped glands on both morphology and molecular levels are not sufficiently investigated. Design: Total of 25 cases of pancreatic well-differentiated neuronendocrine tumor between 2006 and 2013 were retrospectively analyzed. Pre-neoplastic changes (pancreatic intraepithelial lesions, PanIN) were detected in 9 cases. To investigate whether these PanIN like changes in entrapped glands are preneoplastic or reactive, immunohistochemistry for DPC4, p53, P16, EGFR were performed in all cases. In two cases with PanIN-2 lesions, EGFR gene amplification was analyzed by FISH, followed with mutational analyses for EGFR and KRAS genes using DNA extracted from FFPE tissue after microdissection. Epithelial mucin overexpression was evaluated by staining for MUC1, MUC2, MUC5. Results: Entrapped ductules were proven to be present in 18 cases by immunohistochemistry staining for CK19, CEA, and CA19.9. Neuronendocrine components were confirmed by staining for synaptophysin and chromogranin. All 9 cases with PanIN changes in entrpped ducts are significantly larger in size (average 4.5 cm, range 3.0-6.6 cm) compared to PanIn negative tumors (average 2.0 cm, range 1.5-3.5 cm). In two cases, entrapped ducts showed extensive proliferation and acquired at least PanIN-2 like changes with profound papillary structures and moderate nuclear atypia. Positive EGFR immunostaining was detected in 6 of 9 PanIN lesions (including two PanIN2 lesions), among which 4 exhibited diffuse 2+ or 3+ immunoreactivity. However, EGFR gene amplification was only detected in one PanIN2 lesion. Mutations in K-RAS were detected in both PanIN-2 lesions. No mutations were found in the matched nonlesional ductal areas, suggesting that mutations were acquired during transformation. Immunohistochemically, two PanIN2 lesions expressed MUC1 and MUC5, one PanIN2 lesion had weaker staining of P16. No lesions showed aberrant P53 expression, or loss of DPC4 staining. Conclusions: Entrapped ducts in pancreatic neuronendocrine tumor can undergo extensive proliferation and acquire PanIN-2 like morphology, apposing challenges in distinguishing from true mixed ductal-endocrine neoplasms. Molecular and immunohistochemical evidences support these lesions to be pre-malignant rather than reactive, and are found in larger size tumors. Further investigation are needed to understand the significance of this pre-malignant changes.
